Pub. Date:
National Academies Press


Current price is , Original price is $64.0. You

Temporarily Out of Stock Online

Please check back later for updated availability.


Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide.

The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.

Product Details

ISBN-13: 9780309437998
Publisher: National Academies Press
Publication date: 07/01/2016
Pages: 186
Product dimensions: 6.00(w) x 8.90(h) x 0.50(d)

Table of Contents

Acronyms xiii

Summary 1

1 Introduction 13

The Global Burden of Hepatitis B and C Virus Infections 16

The Committee's Charge 20

Disease Control, Elimination, and Eradication 22

References 28

2 The Elimination of Hepatitis B 33

Epidemiology of Hepatitis B 33

The Feasibility of Eliminating the Public Health Problem of Hepatitis B 41

Ending Transmission of Hepatitis B 45

Preventing Complications and Deaths Among the Chronically Infected 56

Crosscutting Barriers to Hepatitis B Elimination 60

References 70

3 The Elimination of Hepatitis C 83

Epidemiology of Hepatitis C 83

The Feasibility of Eliminating the Public Health Problem of Hepatitis C 87

Ending Transmission of Hepatitis C 89

Eliminating Chronic Hepatitis C 95

Reducing Morbidity and Mortality from Hepatitis C 99

Crosscutting Barriers to Hepatitis C Elimination 105

References 118

4 Conclusion 135

References 137


A Committee Meeting 1 Agenda 139

B Committee Meeting 2 Agenda 143

C Committee Biographies 147

D Glossary 157

Customer Reviews